EGFR and neoplasm: Furthermore, ORR and R0 resection rates were increased by Panitumumab (68).The superior OS despite similar PFS rate of EGFR blockade compared to VEGFR inhibition in left-sided RAS WT tumors might be explained by deeper and earlier responses, expressed as early tumor shrinkage (ETS) and depth of response (DpR), according to a retrospective analysis and additional mathematical modeling (69–71).